A camparative study effectiveness topical minoxidil nanosuspention and minoxidil 2% solution in the treatment of alopecia androgenetic

Kermanshah University of Medical Sciences0 个研究点目标入组 140 人开始时间: 待定最近更新: 2018年9月11日

试验速览

暂无简介。

•1. Signature of written consent for participation in the study
•2-Age between 18-55 years
•3-The presence of alopecia androgenetic in male or female
•4-There is no other disorder that causes hair loss such as telogeny, echolinate or scarring hair (like lichen planus)
•Class 1-4 in the Fitzpatrick Classification for Skin Type and Grade 3-6 Hair Loss for Men in the Norwood Hamilton Classification and Grade 2-3 Hair Loss for Women in the Ludwing Classification, Non-Use of Finasteride, Anti-Androgenetics, Local Estrogen , Progesterone, tamoxifen, anabolic steroids, potent potent medications for hyperkeratosis, oral glucocorticoid, lithium, phenothiazines within 3 months before the start of the study

•1-Pregnancy
•2-lactation
•3-Using of anabolic steroids in the last 6month
•4-Using of topical minoxidil in the last 6month
•5-Using of antiandrogenetic drugs in the last 6 month
•6-Using of the drugs who make hyper keratosis as like as systemic corticosteroids in the last 6 month
•7-Dont be principled to curative protocol
•8-Hair transplantation
•9-Collagen vascular disease or HIV
•10-Endocrinopathy like PCO, Hypotyroid

发起方